I invested in cldx when it was in the 2s (average 2.79). I still like it though I have been starting to look for other biotechs that have been similarly under the radar and that have a chance to rise from low valuation with good science. I'm currently in LGND and TSRX, but the one I'm getting more and more excited about is ecyt. Endocyte's drugs are similar to cdx-011in that they have a specific target, but use the folate receptor instead of antibodies to target cancer cells. Their small molecule drugs have better penetration into tumor tissue than the larger antibodies and the clinical and preclinical data looks very impressive to me. In fact it reminds me a lot of CLDX. ECYT will have its first drug approved (most likely) by EMA later this year and the same drug is in Ph III here in the US, and will likely be approved ~2015.
Any thoughts on ECYT or other version of old CLDX, i.e. good undervalued biotech with strong science?
Sentiment: Strong Buy
ECYT draw my attention too, but they have partnership with MRK so, they're about getting royalties only, and, therefore I've a problem with valuation,- it is not clear to me can the p/s get up to 15-16 or much higher.
Royalties are 50% of profit in US and an additional $880 mill in milestones. not bad, and the more exciting of drug, in which they attach tubulysin to the folate receptor ligand is fully owned by ECYT, and I think may be a game changer if safety issues are not getting in the way. What I also like is that, just like cdx-011, the effect of the current Ph III drug depends on expression levels of the folate receptor (in cdx-011's case GPNMB). This seems to validate the whole approach. They are also about to target Triple negative BC, and their drug would be synergistic with cdx-011. Exciting.....
this May article did NOT help them although they seem to have bounced off the recent high 11, 12 low...
Endocyte, Inc. (ECYT) reported first quarter 2013 net loss per share of 11 cents, wider than the Zacks Consensus Estimate of a loss of 5 cents but narrower than the year-ago loss of 27 cents.
First quarter 2013 revenues were $14.5 million compared with no revenues in the first quarter 2012. Revenues comprised solely of collaboration revenues. Revenues surpassed the Zacks Consensus Estimate of $14 million.
In the reported quarter, research and development expenses were $12.3 million, up 92.2%. The company’s effort to develop its pipeline was primarily responsible for the increase. In the reported quarter, general and administrative (G&A) expenses jumped 103.2% to $6.3 million. The increase was attributable to establishing commercial capability. An increase in compensation expenses was also responsible for pushing G&A costs up.
In 2012, Endocyte submitted a marketing authorization application (MAA) seeking approval for vintafolide for platinum-resistant ovarian cancer. The company is also seeking EU approval for a folate-targeted molecular imaging agent, etarfolatide. Both were granted orphan drug status in the EU in 2012. The company expects a decision from the European Commission on both candidates in the fourth quarter of 2013.
Endocyte and its partner Merck & Co. Inc. (MRK) will initiate a phase II randomized trial on vintafolide in folate receptor-positive triple negative breast cancer in the fourth quarter of 2013.
For its folate-targeted tubulysin therapeutic, Endocyte will file an investigational new drug (IND) application and initiate a study in the third quarter of 2013.
Endocyte maintained its cash, cash equivalents and investments guidance in the range of $145 - $160 million as on Dec 31, 2013.
Endocyte carries a Zacks Rank #4 (Sell). Currently, companies like Lannett Company, Inc. (LCI) and Catalyst Pharmaceutical Partners Inc. (CPRX) look mo
this is intriguing to me!
PHILADELPHIA, April 25, 2013 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy in cancer and other serious diseases, today announced that the investigational molecular imaging agent etarfolatide (EC20) may identify and differentiate inflammatory from non-inflammatory disease states of osteoarthritis (OA). The results of this study, conducted under the leadership of Virginia Byers Kraus, M.D., Ph.D., professor of medicine at Duke University, were presented at the OARSI 2013 World Congress on Osteoarthritis in Philadelphia.
"Imaging of OA patients with etarfolatide enables non-invasive, full-body identification of joints that are currently experiencing active inflammation and therefore suffering from its damaging consequences," said Philip Low, Ph.D., Endocyte's chief science officer and co-author of the abstract. "Activated macrophages overexpress folate receptor ß and thereby can be imaged by the folate-targeted etarfolatide. The data from this study demonstrate that macrophages are involved in OA, and that drugs targeting activated macrophages and their inflammatory pathways may be used to decrease OA symptoms and reduce joint deterioration."
The study evaluated the association of etarfolatide uptake with radiographic and clinical measures of OA severity, including joint space narrowing, osteophyte formation and severity of joint symptoms such as pain, aching and stiffness.
Activated macrophages, imaged with etarfolatide, were detected in 76 percent of osteoarthritic knees. Intensity of uptake from the etarfolatide images strongly correlated with joint space narrowing (p=0.006), osteophyte severity (p=0.011) and pain and stiffness (p